Cresset Asset Management’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-1,432
Closed -$206K – 1837
2024
Q4
$206K Sell
1,432
-1,182
-45% -$169K ﹤0.01% 1551
2024
Q3
$389K Buy
2,614
+674
+35% +$96.6K ﹤0.01% 1671
2024
Q2
$245K Sell
1,940
-121
-6% -$19K ﹤0.01% 1809
2024
Q1
$379K Buy
2,061
+712
+53% +$136K ﹤0.01% 1473
2023
Q4
$243K Buy
+1,349
New +$210K ﹤0.01% 1597
2022
Q1
– Sell
-795
Closed -$212K – 1115
2021
Q4
$212K Sell
795
-270
-25% -$72.7K ﹤0.01% 1024
2021
Q3
$308K Buy
1,065
+44
+4% +$11.3K ﹤0.01% 835
2021
Q2
$204K Buy
+1,021
New +$198K ﹤0.01% 946
2019
Q2
– Sell
-66
Closed -$4K – 1411
2019
Q1
$4K Buy
66
+5
+8% +$288 ﹤0.01% 1443
2018
Q4
$3K Buy
+61
New +$3.58K ﹤0.01% 1209

Other funds holding RGEN

Cresset Asset Management's RGEN Position: Q1 2025 in Review

Cresset Asset Management sold out of Repligen (RGEN) in Q1 2025, closing a stake of 1,432 shares — an estimated $206K sold.

Cresset Asset Management first reported a position in RGEN in Q4 2018 and held it in 10 quarters. The position peaked at $389K in Q3 2024. 442 funds tracked by Wall St. Rank hold RGEN as of Q1 2025.

  • Cresset Asset Management reported no remaining Repligen position as of Q1 2025 after selling out during the quarter.
  • Cresset Asset Management sold 1,432 Repligen shares in Q1 2025, an estimated $206K.
  • Cresset Asset Management first reported a position in Repligen in Q4 2018 and held it in 10 quarters.
  • Cresset Asset Management's Repligen position peaked at $389K in Q3 2024.
  • 442 funds tracked by Wall St. Rank held Repligen as of Q1 2025.

Based on Cresset Asset Management's 13F filing for Q1 2025, filed 13 May 2025.